Azhar Kalim has been appointed chief commercial officer, Quotient Clinical. Mr. Kalim will lead the commercial team focusing on Quotient’s strategy to further develop its global commercial footprint following two recent U.S. acquisitions.
 
Quotient’s capabilities include formulation development, GMP drug product manufacturing and early stage clinical trials. The company recently acquired SeaView Research, a specialist early phase clinical pharmacology business, and QS Pharma, a small molecule formulation development and manufacturing business.
 
Mr. Kalim will be responsible for global commercial activities to support Quotient’s integrated services. He will direct the global commercial team in terms of strategic marketing, business development, innovation, key account management, and customer service to biotech and pharmaceutical clients across the globe.
 
Mark Egerton, chief executive officer, Quotient, said, “Azhar has over 25 years’ experience in the drug development services sector, as a leader in expanding research capabilities and creating unique service offerings to the biopharma industry. Quotient takes pride in being a highly customer focused organisation and we are delighted to welcome Azhar in this vital role at an exciting point in the company’s development. I look forward to working with him on a continued journey of growth and success.”